Cancer Biotech Elicio Finds Way to Public Markets via Reverse Merger of Angion
Cancer immunotherapy developer Elicio Therapeutics finally gets a public market listing to fund its clinical research. But instead of the traditional IPO it’s been looking for, the biotech is going…
Read more »